ITMI20031201A0 - EPITOPES OF THE PP65 PROTEIN OF CYTOMEGALOVIRUS - Google Patents

EPITOPES OF THE PP65 PROTEIN OF CYTOMEGALOVIRUS

Info

Publication number
ITMI20031201A0
ITMI20031201A0 IT2003MI001201A ITMI20031201A ITMI20031201A0 IT MI20031201 A0 ITMI20031201 A0 IT MI20031201A0 IT 2003MI001201 A IT2003MI001201 A IT 2003MI001201A IT MI20031201 A ITMI20031201 A IT MI20031201A IT MI20031201 A0 ITMI20031201 A0 IT MI20031201A0
Authority
IT
Italy
Prior art keywords
cytomegalovirus
epitopes
protein
Prior art date
Application number
IT2003MI001201A
Other languages
Italian (it)
Inventor
Fabrizio Manca
Pira Giuseppina Li
Laura Bottone
Original Assignee
Istituto Giannina Gaslini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Giannina Gaslini filed Critical Istituto Giannina Gaslini
Priority to IT001201A priority Critical patent/ITMI20031201A1/en
Publication of ITMI20031201A0 publication Critical patent/ITMI20031201A0/en
Priority to PCT/IB2004/001918 priority patent/WO2004111080A1/en
Publication of ITMI20031201A1 publication Critical patent/ITMI20031201A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
IT001201A 2003-06-13 2003-06-13 EPITOPES OF CITOMEGALOVIRUS PP65 PROTEIN ITMI20031201A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT001201A ITMI20031201A1 (en) 2003-06-13 2003-06-13 EPITOPES OF CITOMEGALOVIRUS PP65 PROTEIN
PCT/IB2004/001918 WO2004111080A1 (en) 2003-06-13 2004-06-10 Epitopes of the cytomegalovirus pp65 protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001201A ITMI20031201A1 (en) 2003-06-13 2003-06-13 EPITOPES OF CITOMEGALOVIRUS PP65 PROTEIN

Publications (2)

Publication Number Publication Date
ITMI20031201A0 true ITMI20031201A0 (en) 2003-06-13
ITMI20031201A1 ITMI20031201A1 (en) 2004-12-14

Family

ID=30131210

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001201A ITMI20031201A1 (en) 2003-06-13 2003-06-13 EPITOPES OF CITOMEGALOVIRUS PP65 PROTEIN

Country Status (2)

Country Link
IT (1) ITMI20031201A1 (en)
WO (1) WO2004111080A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950056B2 (en) 2013-09-24 2018-04-24 Duke University Compositions, methods and kits for eliciting an immune response
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2019061297A1 (en) 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 Cd4 helper t-cell epitope fusion peptide and vaccine thereof
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (en) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 Human cytomegalovirus gb polypeptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5963500A (en) * 1999-06-04 2000-12-28 Florian Kern Peptides for vaccinating against human cmv
DE10009341A1 (en) * 2000-02-22 2001-09-06 Florian Kern Method for antigen-specific stimulation of T lymphocytes
JP2005527506A (en) * 2002-02-28 2005-09-15 インターツェル・アクチェンゲゼルシャフト Ligand E. G. T cell epitope isolation method

Also Published As

Publication number Publication date
ITMI20031201A1 (en) 2004-12-14
WO2004111080A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
NO20044347L (en) Anti-alfavbeta6 antibody
DK1599504T3 (en) Modified antibody
DE502004001401D1 (en) cyclone
DE60222658D1 (en) MONOCLONAL ANTI-CD-40 ANTIBODY
IS7706A (en) lens
IS8266A (en) Modified human IGF-1R antibody
DE602004022855D1 (en) INTERLEUKIN-10 ANTIBODY
DE60233024D1 (en) dry toner
DE602004002987D1 (en) The lens
DK1752470T3 (en) GAG-binding proteins
DE50204020D1 (en) MICROTOME
NO20034452L (en) Disease-associated protein
EE200300569A (en) CD44v6-specific antibodies
DE60200529D1 (en) Hydrophobic object
DE50302514D1 (en) stereomicroscope
FR2820671B1 (en) HOLDER PISTON
ATE513564T1 (en) IMMUNOGENIC RECOMBINANT ANTIBODY
ITMI20031201A0 (en) EPITOPES OF THE PP65 PROTEIN OF CYTOMEGALOVIRUS
FR2820673B1 (en) HOLDER PISTON
DE50202621D1 (en) CENTRIFUGE
DE50200752D1 (en) MICROTOME
FR2820672B1 (en) HOLDER PISTON
FR2820669B1 (en) HOLDER PISTON
ITMI20041811A1 (en) COUPLE LIMITATION JOINT
DE60220164D1 (en) CONSOMMÉ POWDER